Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets
- First Online:
- Cite this article as:
- Paulsson, J.F., Andersson, A., Westermark, P. et al. Diabetologia (2006) 49: 1237. doi:10.1007/s00125-006-0206-7
- 640 Downloads
Islet amyloid is a frequent finding in the islets of Langerhans of individuals with type 2 diabetes. The main amyloid constituent is the beta cell-derived polypeptide hormone islet amyloid polypeptide (IAPP). In general, amyloid refers to an extracellular deposit of a congophilic material, but intracellular amyloid is seen in some beta cells of transgenic mice expressing the gene for human IAPP and in human islets transplanted into nude mice. The aim of this study was to immunohistochemically characterise the intracellular amyloid.
Antisera against the N- and C-terminal processing sites of proIAPP (which were therefore specific for proIAPP), the C-terminal flanking peptide and mature IAPP were used for immunoelectron microscopy.
Fibrillar aggregates were seen in the halo region of the secretory granules in some beta cells in human IAPP transgenic mice. These aggregates were labelled with proIAPP-specific antisera. Also, proIAPP reactivity was more widespread in the intracellular amyloid-like aggregates in beta cells of transgenic mice than in human islet transplants, in which the intracellular amyloid-like deposits were larger, but the proIAPP labelling was restricted to small spots within the amyloid deposits.
We suggest that proIAPP forms the first amyloid fibrils and that this can occur already in the secretory granules of the beta cells. The proIAPP-derived fibrils can act as seed for further amyloid formation, now made up by IAPP. The observed difference between human islet transplants and human IAPP transgenic animals may reflect differences in stages of amyloid development.
KeywordsAmyloidBeta cell granuleElectron microscopyHuman islets of LangerhansHuman islet transplantIAPPIntracellular amyloidIslet amyloid polypeptideProIAPPPro-islet amyloid polypeptideType 2 diabetes
islet amyloid polypeptide
peptidylglycine alpha-amidating monooxygenase
Islet amyloid is strongly associated with type 2 diabetes and is present in a great majority of diabetic individuals post mortem . In 1986, islet amyloid polypeptide (IAPP), a peptide 37 amino acids in length, was identified as the main component of islet amyloid . IAPP is produced as a precursor peptide, proIAPP, consisting of 67 residues. ProIAPP is enzymatically processed by the converting enzymes prohormone convertase 2 and 1/3 (PC2 and PC1/3) , which cleave proIAPP at the N- and the C-terminus, respectively, at di-basic amino acids [4–6]. This results in the removal of an 11-residue N-terminal flanking peptide and a 16-residue C-terminal flanking peptide. Following this reaction, at the C-terminus, carboxypeptidase E removes the lysine and arginine residues, leaving a glycine residue for peptidylglycine alpha-amidating monooxygenase (PAM) to amidate the peptide [7–10]. Formation of a disulphide bridge between cysteine residues 2 and 7 is required for full biological activity of mature IAPP .
Insulin and IAPP are stored in the beta cell and are secreted upon stimulation . The same prohormone convertases process proinsulin into insulin. PC1/3 cleaves proinsulin between the B-chain and the C-peptide, giving rise to a processing intermediate termed des-31,32 proinsulin, whereas PC2 cleaves proinsulin between the A-chain and the C-peptide . Secretion of proinsulin and the processing intermediate des-31,32 is elevated in patients with type 2 diabetes [13, 14]. Since insulin and IAPP are processed by the same enzymes and are released simultaneously, plasma levels of proIAPP would also be expected to be raised in these patients.
It is generally assumed that a greater demand for insulin as a result of peripheral insulin resistance forces beta cells to produce proinsulin/proIAPP at a faster rate than the converting enzymes can process these prohormones [15, 16]. However, studies have shown that chronically high levels of circulating NEFAs reduce activation of the prohormone convertases, resulting in aberrant processing of the prohormones .
Amyloid can create disturbances in the organs via different mechanisms, either by induction of apoptosis or by physical obstruction (when large amounts of amyloid are present). Protein aggregation into amyloid fibrils is preceded by the formation of oligomers that are toxic to the cell (so-called ‘protofibrils’) . These fibrillar intermediates are believed to exert the toxic activity associated with amyloid, and cause apoptosis by incorporation into the plasma membrane, where they form pore-like structures that increase the permeability of the membrane, allowing ions to cross the lipid layer [19–22].
Amyloid has classically been described as an extracellular deposit, but several reports indicate that the initial amyloid formation might occur intracellularly, at least for some forms. We have recently reported that expression of the cDNA corresponding to human proIAPP in GH4 cells, a cell line deficient in PC2 and PC1/3 and therefore incapable of processing proIAPP into IAPP, results in the formation of intracellular congophilic material . When the same cDNA is expressed in beta TC-6 cells, a cell line possessing both PC2 and PC1/3, no deposition of amyloid-like material occurs. In human insulinomas and, more interestingly, in human islets transplanted under the renal capsule of nude mice, intracellular accumulations of congophilic amyloid-like deposits have been detected [24, 25]. Intracellular amyloid-like aggregates have also been reported to occur in transgenic mice expressing the gene for human IAPP [26–28]. In general, these mice had either been treated with a combination of growth hormone and dexamethasone or fed a diet high in fat.
This study is an immunohistochemical characterisation at the ultrastructural level of the intracellular amyloid-like aggregates present in transgenic mice expressing the gene for human IAPP and in human islets transplanted into the renal subcapsular space of nude mice. For this, several antibodies specific for different epitopes of human proIAPP were used.
Materials and methods
Animals and diet
Male mice (n=8) expressing the gene for human IAPP but not mouse IAPP (+hIAPP/−mIAPP) were caged individually with free access to water, standard chow (Lactamin; Vadstena, Sweden) and lard (Ellco Food, Kävlinge, Sweden) during a 12/12 h light/dark cycle. This animal model has previously been described in detail . A group of eight control animals of the same strain were housed under the same conditions, with the exception of access to lard. All experiments were approved by the ethics committee of Linköping University. Animals were fed the diets for 11 months. At the end of the study period, the blood glucose level was determined after 16 h fasting in animals fed the high-fat diet (5.1±1.2 mmol/l) and in control animals fed the standard diet (4.4±0.5 mmol/l) (p<0.1). Thereafter, the animals were killed and pancreases were fixed for electron microscopy in 2% paraformaldehyde with 0.25% glutaraldehyde in PBS (137 mmol/l, NaCl, 2.7 mmol/l KCl, 4.3 mmol/l Na2HPO4, 1.4 mmol/l KH2PO4, pH 7.4) for 24 h. Parts of the tissues were post-fixed in OsO4 prior to dehydration and embedding in Epon (Ladd Research Industries, Burlington, VT, USA). For light microscopy, specimens were fixed in 4% of neutral buffered formaldehyde solution and embedded in paraffin.
Human islets transplanted to nude mice
Methods pertaining to the transplantation of under the renal capsule of non-diabetic nude mice have previously been described in detail [25, 29]. Prior to the transplantation procedure, the islets had been isolated and cultured in vitro for a short period of time. After 2–4 weeks, transplants were removed, fixed in 2.5% glutaraldehyde in PBS for 6 h, post-fixed in OsO4, dehydrated and embedded in Epon .
Quantification of cells with intracellular amyloid
The percentage of cells with intracellular amyloid was determined after Congo red staining for four of the +hIAPP/−mIAPP mice fed a high-fat diet. Islets were analysed for the presence of amyloid in five sections from each animal. Cells were counted in amyloid-containing islets and only cells with a nucleus surrounded by cytoplasm were included.
Paraffin-embedded tissue was cut into 8-μm sections, and dried on slides (Plus slides; Histolab, Gothenburg, Sweden). Antigenic retrieval was performed by heat treatment in 10 mmol/l citric acid buffer, pH 6.0. Sections were placed in a container with 500 ml buffer, and autoclaved at 121°C for 20 min. The sections were allowed to adjust to room temperature and endogenous peroxidase was blocked by incubation in 0.3% H2O2 in Tris-buffered saline (TBS; 50 mmol/l Tris–HCl, 150 mmol/l NaCl, pH 7.6). Sections were rinsed three times in TBS and incubated with M30 monoclonal antibodies (M30 cytoDEATH; Roche, Mannheim, Germany) at 1:100 dilution in TBS overnight. The monoclonal M30 recognises a neo-epitope in cytokeratin 18 (CK-18) that becomes accessible upon caspase cleavage during early apoptosis. Sections were washed three times in TBS and incubated in secondary antibody, swine anti-mouse conjugated with HRP/Envision (DakoCytomation, Glostrup, Denmark). The peroxidase was visualised with 3,3′ diaminobenzidine tetrahydrochloride (DAB). After immunolabelling, sections were stained for amyloid with Congo red . Slides were counterstained with Mayer’s nuclear stain, rinsed in absolute alcohol and xylene, and mounted with Mountex (Histolab). The presence of amyloid was established using a Nikon Eclipse E800 (Nikon, Tokyo, Japan) equipped with filters for wavelengths of 560 nm (excitation) and 590 nm (emission).
Antisera used in immunolabelling experiments
Mouse IAPP 1–37
N-terminal processing site
C-terminal processing site
C-terminal flanking peptide
Quantification of cells with intracellular amyloid
Of 330 islets identified in the pancreatic specimens from +hIAPP/−mIAPP mice, 24 contained intracellular amyloid. A total of 8721 cells from the amyloid-containing islets were counted, and the number of cells filled with amyloid in each islet varied from one to four.
Immunoelectron microscopy of cells from +hIAPP/−mIAPP mice
Immunoelectron microscopy of human islets
Islet amyloid is a common pathological feature of type 2 diabetes and is well characterised, but underlying events triggering amyloidogenic processes are not very well defined. In this study, we have characterised amyloid-like structures in beta cells from +hIAPP/−mIAPP mice and human islet grafts using immunoelectron microscopy. Although the amyloid formation might be at different stages in these two models, the intracellular amyloid-like aggregates containing proIAPP are biochemically similar. Intracellular amyloid has not been reported to occur in pancreases recovered post mortem. However, development of the islet lesion in human diabetes is probably a very long-lasting process, and intracellular amyloid may occur at an early stage. In addition, autolytic alterations often make detailed cellular analyses difficult.
Amyloid is generally referred to as an extracellular proteinaceous fibrillar substance with certain characteristic properties . We and others have previously found that deposits of amyloid-like material may be found in the cytoplasm of beta cells of human islets transplanted into nude mice , in insulinoma tumour cells  and in beta cells of +hIAPP/−mIAPP mice . It has also been suggested that these intracellular aggregates may lead to cell death. Formation of any amyloid fibril is a nucleation-dependent process, and preformed fibrils may catalyse the conversion of a soluble protein to its fibrillar form. Human IAPP is a highly amyloidogenic peptide, and the release of insoluble intracellular aggregates into the extracellular space (e.g. by cell death) may stimulate the conversion of secreted IAPP. Consequently, elucidation of the initial step in amyloidogenesis, which may be an intracellular event, is particularly important.
In addition to cell death, there is another possible mechanism by which intracellularly formed fibrils may be released into the extracellular space. In beta cells, insulin is located in the core area and IAPP in the halo region close to the lipid bilayer of the enclosed secretory vesicle . When beta cell granules from +hIAPP/−mIAPP mice fed a high-fat diet were morphologically investigated, fibrillar structures resembling amyloid fibrils were identified in the halo region in a large proportion of the islets. We previously described a similar phenomenon when islets of Langerhans from +hIAPP/−mIAPP mice were cultured in medium containing high levels of NEFAs . In particular, cells cultured in linoleic acid developed aberrant granule morphology. Intragranular fibrils have also been reported in islets cultured at high glucose concentrations . These fibrils may represent the start of IAPP fibrillogenesis, and it is also possible that granules with fibrils may be released at exocytosis. Importantly, fibrils consisting of proIAPP efficiently seed fibril formation from fully processed IAPP (unpublished results).
Using several antibodies specific for different epitopes of the proIAPP molecule we were able to show proIAPP immunoreactivity in the amyloid-like intragranular fibrils and that these fibrils had the morphological characteristics of classical amyloid fibrils. The finding of intragranular fibrils containing proIAPP is interesting. Knight and Miranker showed that the rate of amyloid formation was strongly enhanced when IAPP and phospholipid bilayers were incubated together, and that fibril formation and elongation occurred from the surface of the lipid bilayer . Furthermore, these authors suggested that beta cells exposed to hyperlipidaemia remodulate their membranes by increasing the negative charge. In a recent study, addition of negatively charged phosphatidylserine, a phospholipid component of cellular membranes, accelerated aggregation kinetics of synthetic human IAPP . Considering that proIAPP has a theoretical pI value of 9.51, while that of IAPP is 8.90, proIAPP would be more efficiently attracted to anionic cellular membranes and form fibrils at this site. Given its proximity to a lipid bilayer and its inefficient hormone precursor processing, the halo region of the beta cell granule might just be the perfect milieu for proIAPP fibrillogenesis. Insulin is known to inhibit fibril formation of IAPP in vitro, but nothing is known about the ability of proinsulin or insulin to interfere with amyloidogenesis of proIAPP [33, 38, 39].
The animals in this study probably had chronically high levels of NEFAs in their circulation since they became rapidly obese and continued to gain weight during the whole study. A high-fat diet is an essential factor for the development of amyloid in developed transgenic mouse strains [26, 40]. How a high-fat diet can trigger amyloid deposition is not known. Furukawa et al. have reported that MIN6 cells incubated with chronic high levels of NEFAs release elevated levels of proinsulin but do not express higher levels of proinsulin mRNA . Levels of mRNA for PC1/3 and PC2 were not altered either; thus a deficiency in the activity of the prohormone convertases was proposed. A study on the effect of rosiglitazone and metformin on islet amyloid formation in transgenic mice fed a high-fat diet was recently conducted . These two drugs increase insulin sensitivity and thereby reduce the secretory demands on beta cells. Though treatment with these drugs reduced amyloid mass, it did not prevent amyloid from being formed . The authors concluded that beta cell lesions and amyloid deposition are not secondary to peripheral insulin resistance, but a direct effect of a high concentration of circulating lipids. NEFAs can act directly on the beta cells through the cell surface receptor GPR40 and enhance glucose-stimulated insulin secretion . Lipid content in the circulation can negatively affect the beta cell in many ways, one of the most important being the alteration of prohormone processing.
In addition to intragranular fibrils, larger intracellular aggregates of amyloid-like material were also observed in beta cells of the +hIAPP/−mIAPP mice and the human islet grafts. These amyloid-like structures were denser than the intragranular fibrils. When immunolabelled with antisera specific for proIAPP (A169 and A165) and investigated in an electron microscope, the amyloid-like aggregates in the murine beta cells showed a strong and even labelling pattern. In amyloid in human islet implants, proIAPP reactivity was not as abundant and had a more patchy appearance. The reasons for these differences are unknown.
This work was supported by the Swedish Research Council, the Swedish Diabetes Association, the Family Ernfors Fund, Östergötland County Council and the Foundation in Memory of Lars Hierta.